Podcasts about cleveland clinic lerner college

The June 2025 podcast explores Patient education related to Nutrition Support and interviews Dr. Gail Cresci, Professor of Medicine in the Cleveland Clinic Lerner College of Medicine of the Case Western Reserve University, and Staff in the Departments of Gastroenterology, Hepatology and Nutrition and Inflammation & Immunity at the Cleveland Clinic in Cleveland, OH. Dr. Cresci discusses the components of enteral nutrition and how these ingredients impact the gut microbiome. She presents the findings of her paper titled, “Understanding How Foods and Enteral Feedings Influence the Gut Microbiome” which reviews over 10,000 papers including both in vitro and in vivo studies to provide a great overview of the field. Business Corporate by Alex Menco | alexmenco.net Music promoted by www.free-stock-music.com Creative Commons Attribution 3.0 Unported License creativecommons.org/licenses/by/3.0/deed.en_US June 2025

Send us a textIn this episode, we are joined by Christopher (Chris) Cantrell, a medical student from the Cleveland Clinic Lerner College of Medicine, to discuss the art of communication in medicine, especially in neurology. From communication between provider-to-patient and peer-to-peer to documentation and self-talk, we talk about it all!  Check out our website at www.theneurotransmitters.com to sign up for emails, classes, and quizzes! Would you like to be a guest or suggest a topic? Email us at contact@theneurotransmitters.com Follow our podcast channel on

Our immune system operates like a finely tuned symphony, yet many of us find ourselves out of harmony, vulnerable to persistent infections, autoimmune conditions, and chronic disease. Rather than merely suppressing symptoms, a Functional Medicine approach seeks to identify and address the underlying disruptions driving immune imbalance. Central to this dysfunction is compromised gut health, which undermines immune regulation, while mitochondrial impairment and chronic inflammation further erode the body's capacity for resilience and repair. By restoring balance at the root level, we can cultivate a more robust and adaptive immune system. In this episode, I discuss, along with Dr. Elroy Vojdani and Dr. Leonard Calabrese, how cleaning up our diets, improving gut health, removing toxins, and decreasing stress can do wonders for our immune systems. Dr. Elroy Vojdani is a pioneer in the field of functional medicine and research and is the founder of Regenera Medical, a concierge functional medicine practice in Los Angeles, California. He graduated from USC Keck School of Medicine, is a certified Institute for Functional Medicine Practitioner. Dr. Vojdani has conducted medical scientific research for decades with more than 25 publications in multiple peer-reviewed journals. He is also world-renowned for his research and development of state-of-the-art lab testing in the field of immunology. He recently authored a book entitled “When Food Bites Back” which discusses the role of food immune reactions in the development of autoimmune disease.  Dr. Leonard Calabrese, is an expert in immunology and rheumatology. In fact, he is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Vice Chair of the Department of Rheumatic and Immunologic Diseases. Dr. Calabrese is the director of the RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic and holds joint appointments in the Department of Infectious Diseases and the Wellness Institute. Dr. Calabrese has made significant contributions to science in the fields of chronic viral infections and autoimmunity and vascular inflammatory diseases of the brain. He has received numerous awards and honors for his contributions to the advancements of immunology and wellness. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN10 to save 10%. Full-length episodes can be found here: Boost Your Immunity with These Simple Steps How To Reset Your Immune System At A Cellular Level The Secrets to Creating a Healthy Immune System

On this episode, hear the 2024 updates on COVID-19, long COVID and the latest developments in research in rheumatology. Hosted by Dr. Leonard Calabrese. Intro 0:12 In this episode 0:21 Coming up on Healio Rheuminations 0:56 COVID-19, long COVID and the rheumatologist with Leonard Calabrese, DO 2:19 Questions 3:12 Long COVID 4:46 Calabrese's bias 10:15 The evidence 13:08 Auto antibodies 14:54 Why does the body develop auto antibodies? 17:47 COVID-19 and epidemiologic association 22:25 New clinical entity 26:40 Therapeutic implications 31:00 In conclusion 32:00 Thanks for listening 33:18 Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic. Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

This special episode of RealTalk MS is sponsored by EMD Serono and is only intended for a U.S. audience. EMD Serono is the healthcare business of Merck, KGaA, Darmstadt, Germany, in the United States and Canada. In this special episode of RealTalk MS, Dr. Mary Rensel and Amanda Montague join me to explore HCP (Healthcare Provider) burnout and patient empowerment; and we'll be taking a close look at how patients and their healthcare providers can work together to support one another. Dr. Mary Rensel is an Assistant Professor of Medicine at the Cleveland Clinic Lerner College of Medicine and Director of Pediatric Multiple Sclerosis and Wellness at the Mellen Center for Multiple Sclerosis at the Cleveland Clinic. Amanda Montague is a global thought leader and Chief Mission Officer at the Multiple Sclerosis Association of America. Amanda is also an active member of the MS in the 21st Century initiative, more commonly known as MS21. MS21 is a Merck KGaA, Darmstadt, Germany, initiative involving healthcare professionals, or HCPs, and patient advocates. To learn more about MS in the 21st Century, please visit www.msinthe21stcentury.com.

ESO's Electronic Health Record makes it easy to produce high-quality EMS clinical documentation, saving your team time and ensuring accuracy. To learn more, visit eso.com/ehr/pod. Hosts: Bradley Dean and David Blevins Guest: Dr. Andrew McCoy, MD, assistant professor of Emergency Medicine; medical director for Shoreline Medic One and AMR Puget Sound Operations; program director for the University of Washington EMS Fellowship; and medical director for the Resuscitation Academy. Episode Summary: In this episode, Bradley Dean and David Blevins sit down with Dr. Andrew McCoy to explore everything about resuscitation and the Resuscitation Academy (RA). Dr. McCoy shares the history of the RA and its mission to improve survival rates for sudden cardiac arrest in communities. With a focus on resuscitation science and EMS education, the discussion covers the impact of the CAROL Act, improvements in local EMS practices, and the ongoing growth of the RA, including the innovative Lighthouse Program. Guest Bio: Dr. Andrew McCoy is an assistant professor of Emergency Medicine at the University of Washington and has been a faculty member at the Resuscitation Academy in Seattle for 10 years. A graduate of the Cleveland Clinic Lerner College of Medicine, Dr. McCoy completed his Emergency Medicine residency in Buffalo, New York, before moving to Seattle for an EMS fellowship. He now serves as medical director for Shoreline Medic One, American Medical Response (AMR) Puget Sound Operations, and the Resuscitation Academy, where he helps EMS professionals improve cardiac arrest survival rates across the country Points of Discussion: What is the Resuscitation Academy (RA), and its history? Bradley's experience with the RA and improvements made in his community. The future of the RA: How the CAROL Act will influence resuscitation efforts and the opportunities for growth. The Lighthouse Program and its role in driving continuous improvement in resuscitation practices. Resources Mentioned: Resuscitation Academy: www.resuscitationacademy.org CAROL Act: Barr's CAROL Act American Heart Association – Resuscitation Guidelines: CPR and ECC Guidelines CARES Registry: CARES Registry RESUSCITATE!: Resuscitate! Book Key Takeaways: Sudden cardiac arrest is one of the leading causes of death, but survival rates vary significantly from community to community. The Resuscitation Academy's mission is to train EMS personnel and equip them with the tools and knowledge needed to improve survival rates. With programs like the Lighthouse Initiative and new legislation like the CAROL Act, the future of resuscitation looks promising, offering pathways to reduce preventable deaths from cardiac arrest. Listen in to learn more about how your community can improve resuscitation outcomes and get involved with the Resuscitation Academy.

ImmunoCAST welcomes Dr. Michael Benninger, Professor and Former Chair of the Department of Otolaryngology-Head and Neck Surgery in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, as a guest expert speaker on this special Allergy After Dark episode. With over 200 publications, Dr. Benninger is an expert on respiratory allergies and their impact on sexual function in patients. Tune in to this episode, where Dr. Benninger joins Gary and Luke to discuss the importance of understanding a patient's allergic triggers and how they may impact a more intimate side of their life. Episode resources and references available at https://www.thermofisher.com/phadia/us/en/resources/immunocast/s2e7.html

In this episode, we discuss the challenges of explanting aortic grafts, the diagnosis and management of infected aortic grafts, as well as tips and tricks for once we're in the operating room.   Interviewers/Editors: Mark Basilious, MD Candidate (@markrbasilious) Eva Urrechaga, MD (@urrechisme) Sharif Ellozy, MD (@SharifEllozy)   Guests: Dr. Francis Caputo (@FrankCaputoMD) is an Associate Professor of Surgery at the Cleveland Clinic Lerner College of Medicine, Vascular Surgery Director of the Aorta Center, and Program Director of the Vascular Surgery Training Programs. His clinical interests include complex open and endovascular repair of thoracic, thoracoabdominal, and abdominal aortic aneurysms, management of thoracic dissection, and endovascular and open repair of failed endograft. Dr. Caputo earned his medical degree from the University of Medicine and Dentistry New Jersey, Newark, NJ, where he also served his surgical residency and two years as a National Institutes of Health research fellow. He completed his fellowship in vascular surgery at Barnes-Jewish Hospital of Washington University, St. Louis, MO and joined the Cleveland Clinic medical staff in 2018.    Dr. Peter Rossi (@peterjrossi) is a Professor of Surgery, Radiology, and Orthopedic Surgery, and Chief of the Division of Vascular and Endovascular Surgery at the Medical College of Wisconsin. His primary research and clinical interests are in complex  “re-do” and revision surgery, including for thoracoabdominal and abdominal aortic aneurysms, carotid artery surgery, and renal and mesenteric arterial disease, as well as vascular reconstruction for complicated soft tissue sarcomas. Dr. Rossi completed medical school at the University of Illinois College of Medicine before completing his general surgery training at the University of Chicago and his vascular surgery training at the Medical College of Wisconsin, where he has been a member of the faculty since 2009.  Dr. Xavier Berard (@XavierBerardMD)  is a French vascular surgeon who has been a Consultant in the Department of Vascular Surgery and Professor of Vascular and Endovascular Surgery in Bordeaux University Hospital in Bordeaux, France since 2010 and a full Professor of Vascular Surgery at the University of Bordeaux since 2016. He has also completed a PhD in Vascular Biomaterials and in 2010 worked as a research fellow at Lausanne University Hospital in Switzerland. He has been board certified by the French College of Vascular and Endovascular Surgeons since 2008 and by the European Society for Vascular and Endovascular Surgery since 2010. He has served as an examiner for the FEBVS exam since 2014 and as a reviewer for the European Journal of Vascular and Endovascular Surgery since 2016. Additionally, he is a member of the ESVS guidelines writing group for vascular graft infection and AAA.  His personal surgical interests include open surgery of (thoraco)abdominal aneurysms, redo aortic surgery, infections in vascular surgery, EVAR explantation, and biomaterials. He works closely with Institut Bergonié Bordeaux Cancer Center for sarcomas. You can see educational videos and learn more about Dr. Xavier Berard here. Helpful links and resources: Video of explantation of infected chimney EVAR with duodenal fistula (courtesy of Dr. Berard) Video of reimplanting the IMA after explanting an infected graft Video of explantation of infected graft with suprarenal fixation Videos of using the syringe technique to remove an aortic stent graft here and here (courtesy of Dr. Berard) References Kim YW. Aortic Endograft Infection: Diagnosis and Management. Vasc Specialist Int. 2023 Sep 21;39:26. doi: 10.5758/vsi.230071. PMID: 37732343; PMCID: PMC10512004. Papas TT. Patient Selection Is Essential for Explantation of Infected Abdominal Aortic Endografts. Angiology. 2023 Nov 23:33197231218622. doi: 10.1177/00033197231218622. Epub ahead of print. PMID: 37995099. Anagnostopoulos A, Mayer F, Ledergerber B, Bergadà-Pijuan J, Husmann L, Mestres CA, Rancic Z, Hasse B; VASGRA Cohort Study. Editor's Choice - Validation of the Management of Aortic Graft Infection Collaboration (MAGIC) Criteria for the Diagnosis of Vascular Graft/Endograft Infection: Results from the Prospective Vascular Graft Cohort Study. Eur J Vasc Endovasc Surg. 2021 Aug;62(2):251-257. doi: 10.1016/j.ejvs.2021.05.010. Epub 2021 Jun 14. PMID: 34140225. Lumsden AB. Explant of the Aortic Endograft: Today's Solutions, Tomorrow's Problems. Methodist Debakey Cardiovasc J. 2023 Mar 7;19(2):38-48. doi: 10.14797/mdcvj.1176. PMID: 36936357; PMCID: PMC10022536. Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.  

Tune in to the second part of this amazing episode with Dr. Leonard Calabrese. This is a throwback to an episode we recorded last year that deserves a second share! Here, Dr. Amigues and Dr. Calabrese dive deep into QiGong and it's incredible healing benefits.Qigong is a coordinated body posture and movement practice that combines elements of martial arts, spirituality, and traditional Chinese medicine. Dr. Calabrese shares his journey of exploring integrative techniques to improve the well-being of patients with medically unexplained syndromes. Dr. Calabrese also emphasizes the importance of the healing effect, which goes beyond the placebo effect, and empowers patients to take control of their health. He highlights the need to integrate mind-body practices, such as meditation and Qigong, into medical education and patient care.~ About Dr. Calabrese ~Dr. Len Calabrese is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine and the di- rector of the R.J. Fasenmyer Center for Clinical Immunology. He has been practicing clinical immunology and engaging in research and education at the Cleveland Clinic for over 35 years. He is the author of over 300 manuscripts, chapters and editorials on the subject of clinical immunology.LINKS:How to optimize your immune system: Maintaining a Healthy Immune System PDF by Dr. CalabreseQiGong ressource: www.qigongforvitality.com/Meditation Resource: Stress Free Now________________________________________________________________________________________________Join the community and follow UnabridgedMD on social media!Instagram: @unabridgedmdFacebook: @UnabridgedMDTiktok: @unabridgedmdIf you live in Colorado and are looking for a rheumatologist to help you achieve disease remission, email or contact us at UnabridgedMD.com. We are the first direct care rheumatology in Colorado and can see you within a week!Click here to get in touch: https://www.unabridgedmd.comOr give us a call: 303-731-4006If you live in Colorado and are looking for a rheumatologist to help you achieve disease remission, email or contact us at UnabridgedMD.com. We are the first direct care rheumatology in Colorado and can see you within a week!

This week, we are replaying this golden episode with Dr. Leonard Calabrese! It has so many impactful takeaways that align with the UnabridgedMD mission, and we don't want you to miss it. Stay tuned for part two of this episode where Dr. Amigues and Dr. Calabresi will dive deep into QiGong.Dr. Calabresi discusses his work in clinical immunology and the importance of empowering patients to improve their immune system. He explains the concept of Qigong and its role in promoting wellness. Dr. Calabresi also shares his research on the effects of mindfulness meditation on gene expression and stress reduction. He emphasizes the need for evidence-based wellness behaviors and the potential for these practices to enhance overall well-being.Dr. Len Calabrese is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine and the di- rector of the R.J. Fasenmyer Center for Clinical Immunology. He has been practicing clinical immunology and engaging in research and education at the Cleveland Clinic for over 35 years. He is the author of over 300 manuscripts, chapters and editorials on the subject of clinical immunology.LINKS:How to optimize your immune system: Maintaining a Healthy Immune System PDF by Dr. CalabreseQiGong ressource: www.qigongforvitality.com/Meditation Resource: Stress Free Now________________________________________________________________________________________________Join the community and follow UnabridgedMD on social media!Instagram: @unabridgedmdFacebook: @UnabridgedMDTiktok: @unabridgedmdIf you live in Colorado and are looking for a rheumatologist to help you achieve disease remission, email or contact us at UnabridgedMD.com. We are the first direct care rheumatology in Colorado and can see you within a week!Click here to get in touch: https://www.unabridgedmd.comOr give us a call: 303-731-4006If you live in Colorado and are looking for a rheumatologist to help you achieve disease remission, email or contact us at UnabridgedMD.com. We are the first direct care rheumatology in Colorado and can see you within a week!

Today's episode is going to focus on the level I clinical trials evaluating the Bridge-Enhanced ACL Repair or “BEAR”, including an update from the ongoing multicenter RCT – the BEAR-MOON trial! We are joined today by two outstanding guests! Dr. Brett Owens is a professor of orthopedic surgery at the Brown University Alpert Medical School, Chief of Sports Medicine at Miriam Hospital and the Director of the Rhode Island Cartilage Repair Center.  He is also a team physician for the Providence Bruins and Brown University athletics.Dr. Kurt Spindler is a professor of orthopedic surgery at the Cleveland Clinic Lerner College of Medicine, Director of Clinical Research and Outcomes at the Cleveland Clinic in Florida and a past president of AOSSM. He has also served on numerous NFL committees including the Safety Council and the Research and Innovation Committee.So, without further ado, let's get to the Exhibit Hall!

Dr. Stoller is Chairman of the Education Institute at Cleveland Clinic. He holds the Jean Wall Bennett Professorship of Medicine at Cleveland Clinic Lerner College of Medicine and the Samson Global Leadership Academy Endowed Chair. He is a pulmonary/critical care physician in the Cleveland Clinic Integrated Hospital Institute. He serves as the Senior Associate Dean for Academic Affairs (Cleveland Clinic) in the Case Western Reserve University School of Medicine. In 1979, Dr. Stoller earned a medical degree from Yale University School of Medicine and later completed an internship and residency at Peter Bent Brigham Hospital in Boston. He then completed fellowships in pulmonary/critical medicine (Brigham and Women's Hospital and Yale), clinical epidemiology (Robert Wood Johnson Clinical Scholars Program at Yale), and respiratory intensive care (Respiratory Intensive Care Unit of the Massachusetts General Hospital) before joining the Respiratory Institute Staff at Cleveland Clinic in 1986.Dr. MinhTri Nguyen recently graduated from Cleveland Clinic's Hematology and Oncology Fellowship program.  He has had leadership experiences as the Associate Director of Outpatient Services at Metrohealth's Internal Medicine Department, Chief Resident, and President of the House Officer's Association at MetroHealth. This year, he was named one of Northeast Ohio's Top 25 Under 35 Movers and Shaker's Award.MinhTri has a longstanding interest in emotional intelligence and leadership, with ongoing research in both subject matters related to physician training. He is a certified coach, currently coaching resident physicians and clinical leaders. In the fall, he will be joining Stanford Health Care, where he will practice Hematology/Oncology with University Medical Partners while continuing his academic interests in leadership development for physicians.  A Quote From This Episode"The practice of leadership like medicine (both fields in their own right) is continuous. To be a good practitioner of medicine you need to be in tune with the practice and practice medicine. So the same thing applies to leadership you need to be in tune with the field of leadership and practice leadership."Resources Mentioned in This EpisodeCoursera Course - Andrew Ng on Artificial IntelligenceArticle - The Moral Bucket List by BrooksBook - Better Humans, Better Performance by Rae, Stoller, & KolpBooks - Hidden Potential and Give and Take by GrantBook - The Art of the Impossible by KotlerCommencement Address - Don Berwick, Yale Medical SchoolCommencement Address - Ken Burns, Brandeis UniversityAbout The International Leadership Association (ILA)The ILA was created in 1999 to bring together professionals interested in studying, practicing, and teaching leadership. Register for ILA's 26th Global Conference in Chicago, IL - November 7-10, 2024.About  Scott J. AllenWebsiteWeekly Newsletter: The Leader's EdgeMy Approach to HostingThe views of my guests do not constitute "truth." Nor do they reflect my personal views in some instances. However, they are views to consider, and I hop

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Wilson Tang, MD Many different artificial sweeteners are being consumed by patients; however, this discussion will focus on research around one that has been used in the food industry for a long time, called erythritol. Interestingly, it was found that patients with cardiac problems had the highest levels of erythritol levels in their blood, which prompted further studies on this association. So to learn more about the impact of artificial sweeteners on heart disease and how we can guide patients into consuming less, join Dr. Mary Katherine Cheeley as she speaks with Dr. Wilson Tang, Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Co-Author of the article, titled “The Artificial Sweetener Erythritol and Cardiovascular Event Risk,” published in Nature Medicine in February 2023.

Stephanie Weiss, MD, PhD, FASAM, joins us for this special episode recorded at ASAM's 55th Annual Conference. Dr. Weiss shares her experiences attending ASAM's conferences over the past few years, including the virtual conference in 2020 when she was a Ruth Fox Scholar. She talks about her extensive educational journey and the surprising path to her current job at NIDA. She also discusses her work regarding kratom, kratom use, and how that use differs in the US versus other countries. Dr. Weiss addresses the challenges of interpreting urine drug testing and the complexities of stigma related to addiction.   Dr. Weiss is the staff clinician serving the Translational Addiction Medicine Branch (TAMB) of the NIDA IRP. After earning a PhD in pharmaceutical chemistry from the University of South Florida, Dr. Weiss received her medical degree from Cleveland Clinic Lerner College of Medicine in 2011. She practiced as an emergency physician in Florida before completing fellowships in addiction medicine and medical toxicology, a subspecialty that cares for patients with poisonings, environmental exposures, and overdoses. She also participated in Boston University's Research in Addiction Medicine Scholars Program, which fosters the development of addiction physician scientists. Dr. Weiss assumes responsibility for providing optimal, safe, and ethical care to study participants and clinical support toward the TAMB mission of conducting inpatient and outpatient proof-of-concept human laboratory studies. Her research interests include kratom toxicology, medication misuse, and improving interpretation of urine drug testing. Links: ASAM Annual Conference information Ruth Fox Scholarship Program NIDA – National Institute on Drug Abuse Research in Addiction Medicine Scholars Program American Society of Addiction Medicine (ASAM)   If you or someone you know is struggling with addiction, you are not alone. Treatment is available and recovery is possible. Visit ASAM's Patient Resources page for more information. The information shared in this podcast episode is for educational purposes only and should not be taken as medical advice. The views expressed in this podcast may not be those of the host or ASAM management.

Welcome to The PQI Podcast season 6 finale! As we close out this chapter, we reflect on the survivor stories shared, the clinical insights gained, and the impactful conversations we've had over the last few months. We are thrilled to end this season with special guest Hardeep Phull, MD, to discuss various oncology hot topics, including burnout, financial toxicity, AI, and remaining current with literature.Dr. Phull is the Director of Oncology at Palomar Health, the Alumni Specialty Director at the Cleveland Clinic Lerner College of Medicine, and a Clinical Instructor at the University of California San Diego. He views his ongoing journey in medicine as a series of experiences that have enabled him to appreciate different values, cultures, and viewpoints, keeping him grounded and highly involved in education, mentorship, leadership, and advocacy in the community.You can find articles from Dr. Phull in NCODA's Oncolytics Today here:• The Mental Health Epidemic in Oncologists• Effect of Prior Authorization Rule Remains to be Seen

In a landscape where funding is increasingly difficult to obtain, the importance of conducting research that has the greatest impact has never been more important. In the case of women with MS, a large-scale scoping review,* conducted on behalf of the International Advisory Committee on Clinical Trials in MS, sheds light on the research gaps related to female health. ln this episode, host Brett Drummond of MSTranslate talks with two of its authors -- Lindsay Ross, an assistant professor at the Cleveland Clinic Lerner College of Medicine, and Ruth Ann Marrie, professor of medicine and community health sciences at the University of Manitoba in Canada. *Ross, L., Finlayson, M., Amato, M. P., Cohen, J. A., Hellwig, K., Tintore, M., Vukusic, S., Salter, A., & Marrie, R. A. (2024). Priority setting: women's health topics in multiple sclerosis. Frontiers in neurology, 15, 1355817. https://doi.org/10.3389/fneur.2024.1355817  

Show Summary In this episode, Linda Abraham interviews Christian Essman, Senior Director of Admissions and Financial Aid at Case Western Reserve University Medical School. They discuss the unique aspects of Case Western's three MD programs, the significance of research in the application process, and what makes an applicant stand out. Christian emphasizes the importance of quality experiences and reflections in the application essays and advises applicants to submit their applications when they are in tip-top shape, rather than rushing to submit on the first day. He also discusses the culture at Case Western, describing it as laid-back, balanced, and invested in the success of its students. Show Notes Thanks for tuning into the 571st episode of Admissions Straight Talk. Are you ready to apply to your dream medical schools? Are you competitive at your target programs? Accepted's med school admissions quiz can give you a quick reality check. Just go to accepted.com/medquiz, complete the quiz and you'll not only get an assessment but tips on how to improve your chances of acceptance. Plus, it's all free.  I'm delighted to introduce today's guest, Christian Essman, senior director of admissions and financial aid and fellow podcaster and host of the All Access Med School Admissions Podcast.  Christian, thank you so much for joining me today on Admissions Straight Talk. [1:31] Hi, Linda. Delighted to be here. Thank you for having me. Let's start with some just really basic information about Case Western University's medical school programs. Can you give a 30,000-foot perspective or view of the three MD programs that it offers? [1:39] Certainly. We're a bit unique in that we have not one, not two, but three different pathways to an MD/MD-PhD. The first one is the university program, which is our four-year MD, which is a traditional four-year degree. Then we have our MD-PhD program, which is a medical scientist training program, and that's about eight or nine years. MSTP actually started at Case Western back in the 1950s, by the way. It's the longest NIH-funded program ever in the history of the universe. And then the one in the middle is unique. I don't know if the word boutiquey is a word, but it's boutiquey. Our Cleveland Clinic Lerner College of Medicine. So these are all three Case Western programs. They're under the umbrella of the university and they're all Case Western students, but we have three tracks. So the one in the middle, the Cleveland Clinic Lerner College of Medicine, is a five-year MD and it's for students who really like research. Really, really, really like research. But maybe advancing to an MD-PhD is not an educational goal to be in school for eight or nine years and getting a PhD, but they really like research. And so the reason why it's five years is because they thread research throughout the entire five years that you're there. And at one point students will step away usually after the second year to do 12 months of research with the results of hopefully having some publishable results. And so it's for students who might be considering MD-PhD, maybe they're also applying to MD-PhD. So it's one in the middle there and so that's why we have three different tracks. It's a bit unique. It is unique. I don't know of any other school that has that three structured program. [3:36] When people apply to us in AMCAS, they apply to Case Western and then in the secondary application, they can indicate which program or programs plural that they want to apply to. And so you could apply to the university program and the Cleveland Clinic program and then you get separate admissions decisions. We review them separately. So it's two for one or three for one if you want to think of it that way. But I will say this. Very few students apply to all three. Usually, if you're interested in MD-PhD, that's what you're applying to, and then maybe add in Cleveland Clinic,

Dr. Joseph Iannotti is a prominent figure in the field of orthopedic surgery. As he continues to make significant strides in his illustrious career, he has recently assumed the role of Chief Research and Academic Officer at Cleveland Clinic Florida. His dedication to advancing healthcare is further emphasized by his tenure as the Chief of Staff at Cleveland Clinic Florida for the past five years, where he has played a pivotal role in overseeing and enhancing the hospital's operational excellence. In addition to his clinical role, he holds the esteemed position of Professor of Surgery at the Cleveland Clinic Lerner College of Medicine (CCLCM) at Case Western Reserve University. Dr. Iannotti also occupies the Lang Family Endowed Chair of Orthopedic Surgery. With an impressive career spanning several decades, Dr. Iannotti previously served as the Chairman of the Department of Orthopedic Surgery and Chair of the Orthopedic and Rheumatology Institute at the Cleveland Clinic from 2000 to 2018. His extensive educational background includes earning an MD from Northwestern University in 1979, completing Orthopedic Residency training at the University of Pennsylvania in 1984, and obtaining a PhD in cell biology from the University of Pennsylvania in 1987. Dr. Iannotti is renowned for his groundbreaking work in clinical and basic science research, particularly focusing on innovative treatments for tendon repair and tendon tissue engineering, prosthetic design, software planning, and patient-specific instrumentation. His dedication to advancing the field is evident through his publication of three textbooks and authorship of over 380 original peer-reviewed articles, review articles, and book chapters. Notably, Dr. Iannotti has received numerous accolades, including being a three-time recipient of the Charles Neer Research Award, the Cleveland Clinic 2011 Sones Award for Innovation, and the Cleveland Clinic Lifetime Achievements Award for Innovation in 2019. With approximately 120 U.S. and International patents to his name, he was inducted into the National Academy of Inventors in 2016. Beyond his clinical and research contributions, Dr. Iannotti has been actively involved in various leadership roles within professional organizations. He has served as Past Chair of the Academic Affairs Council and the Board of Directors of the American Academy of Orthopedic Surgery, Past-president of the American Shoulder and Elbow, and Past-chairman of the Board of Trustees of the Journal of Shoulder and Elbow Surgery. Currently, he is a member of the Board of the ASES Foundation, Board of Bio-Florida, and Advisory Board of the School of Business at the University of Miami. Dr. Iannotti also serves as an advisor to other biotechnology companies. Join us as we delve into the wealth of knowledge and experience that Dr. Joseph Lannotti brings to the world of orthopedic surgery and medical innovation. Welcome, Dr. Iannotti!.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to tackle progressive MS, and whether drug trials are truly assessing patients at the right time points. Furthermore, he discussed multi-stage trials, the potential role of Bruton tyrosine kinase (BTK) inhibitors, and how this year's meeting differs from previous ones.  Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page. Episode Breakdown: 1:05 – Overviewing sessions from ACTRIMS Forum 13:10 – Innovating clinical trial design 16:15 – 2023 ACTRIMS vs 2024 ACTRIMS 20:20 – Neurology News Minute 23:30 – Testing combination approaches for progressive MS 26:45 – The impact of timing therapeutic interventions  This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA AdComm to Review Investigational Alzheimer Agent Donanemab and Phase 3 Results Amylyx Mulls Over Pulling AMX0035 Following Disappointing Phase 3 PHOENIX Findings FDA Issues Complete Response Letter for Long-Acting Form of Glatiramer Acetate for Relapsing Multiple Sclerosis Phase 2 PROCEED Trial of PACAP-Targeting Antibody Lu AG09222 in Migraine Announced Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

When a kidney from a deceased donor becomes available, it is scored on a system called the Kidney Donor Profile Index (KDPI). How does the KDPI work and is it accurate at predicting possible transplant survival compared to a lower KDPI donation or a living donor? On this episode, we speak with experts to get the facts.   Nichole Jefferson is a kidney transplant recipient and active member of NKF's Kidney Advocacy Committee. She has attended every Kidney Patient Summit with NKF in Washington, D.C. since 2014, representing the states of Iowa and Texas. Presently, she is the Co-Chair of the NKF Kidney Advocacy Committee's Diversity & Health Equity Advisory Committee. In this position, she shares her experiences and advocates for kidney disease awareness and needs.  This is a way for her to pay it forward to her community.   Anne Huml, MD, MS is a transplant nephrologist and clinical researcher in the Department of Kidney Medicine within the Cleveland Clinic's Glickman Urological and Kidney Institute.  She is an Assistant Professor of Medicine at Cleveland Clinic Lerner College of Medicine. One of her primary research focuses is on health disparities in kidney disease, particularly on access to kidney transplant. She has worked on research teams to: improve access to the kidney transplant waiting list through the use of patient navigators; evaluate deceased donor organ offers to patients at the top of the waiting list; and investigate access to kidney transplant and transplant outcomes in large, national databases.   Additional Resources  Transplantation Resources (Transplants For All) Underutilized Kidneys   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

JCO PO author Dr. Eric Klein shares insights into his JCO PO article, “Performance of a Cell-Free DNA-Based Multi-Cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancers” Host Dr. Rafeh Naqash and Dr. Klein discuss how a multi-cancer detection test may facilitate workup and stratification of cancer risk in symptomatic individuals. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma.   Today, we are excited to be joined by Dr. Eric Klein, Emirates Professor and Chair at the Glickman Urological and Kidney Institute at the Cleveland Clinic Lerner College of Medicine. Dr. Klein is also a distinguished scientist at Grail and author of the JCO Precision Oncology article titled "Performance of a Cell-free DNA-based Multi-cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancer."   Our guest's disclosures will be linked in the transcript.  For the sake of our conversation today, we'll refer to each other using our first names. It's great to have you here today, Eric, and welcome to our podcast.  Dr. Eric Klein: Thanks, Rafeh. I'm happy to be here. Dr. Rafeh Naqash: So today, we're going to try to delve into this very interesting paper. We've had a couple of very interesting podcasts on liquid biopsies, or plan to have a few more. And this is a different aspect of liquid biopsy assessment, and the context here is early cancer detection. Now, the story as it starts, is based on the methylation profile of cancer. Can you tell us, for the sake of our listeners, as we have a very broad audience ranging from trainees to community academic oncologists, what do you understand by methylation profile on a cancer? Dr. Eric Klein: Sure. Happy to start with that. There are lots of cancer signals in the blood. Cancer cells secrete or otherwise supply the bloodstream with DNA that has methylation signals that are specific to cancer. That's a hallmark of cancer-specific mutations. You can look at chromosome fragments, you can look at proteins and mRNA and exosomes and that sort of thing. In Grail's development study, we focused on using methylation because that, as I mentioned, is a fundamental process. A fundamental property of cancer cells is altered methylation. And in our original development studies, that was the strongest signal, the one that allowed us to have the lowest limit of detection when cancer was present, and the one that allowed us to have the best predictive accuracy for the cancer signal origin. Some people think about that as predicting the tumor origin or the tumor type. And that's the basis of Grail's assay, a pan-cancer methylation profile. Dr. Rafeh Naqash: Excellent. And now to understand some of the methodology that you used here, before we go into the details because there's a lot of sensitivity and specificity obviously associated with any cancer detection test, and you want a high sensitivity and specificity. And the idea here is that this would help in triaging patients appropriately using this non-invasive tool. Could you tell us the patient population that you were trying to enroll in this study? And I think there is, again, background to other studies that you have done using the Grail test. Could you put that into context of this specific study?  Dr. Eric Klein: Sure. The population in this particular publication was from substudy 3 of a much bigger study called the Circulating Cell-free Genome Atlas, or CCGA. That was a discovery, refinement, and validation study of this methylation-based signal. And in total, all three substudies together was about 15,000 people, and it was a case-control study. About 10,000 of the individuals enrolled had cancer and about 5000 were not known to have cancer and served as controls. In the first part of the study, substudy 1 of CCGA, we simply asked the question: In individuals with known cancer, could we detect a methylation-based signal? And the answer was ‘yes'. The second question was: In patients not known to have cancer, did we not see a signal? And by and large, the answer was ‘yes'. The second substudy was a refinement and validation of the original methylation-based test. And then this study, what we refer to colloquially as CCGA3, or substudy 3 of CCGA, was the final validation that underlies the methylation assay that is currently on the market.   So, in CCGA3, we determined what the performance characteristics of this test were in a case-control fashion, and what we found, importantly, was that the specificity was very high, at 99.5%, which means the false-positive rate is only half a percent. We found that the overall sensitivity for detecting cancer varied by stage, but when you included all stages 1 to 4, the overall sensitivity for detecting known cancers was about 51%. We found that the ability of this methylation-based test to predict the correct cancer signal origin was right around 90%. And finally, the final performance characteristic was really important, which is the positive predictive value. So in individuals who had a positive signal detected, the positive predictive value was 43%, which compares very favorably to existing screening tests, all of which are below 10%.  That was the background, and the development there was focused on eventually developing a test that will screen the general population, the asymptomatic population, at risk for developing cancer. This is a subset of CCGA3, or the substudy 3 of CCGA, where we looked at the performance characteristics of this test in individuals who had symptoms that could possibly be due to cancer and individuals who had underlying medical conditions that could result in a false positive, and individuals in particular over age 65, because the risk of cancer goes up over age 65. Dr. Rafeh Naqash: Thank you for explaining that. So, again, going to some of the finer details in this study, you mentioned some very important numbers here, 99%, 63%, or something in that range for sensitivity and specificity. Could you explain a little more on that based on the cancer types? As you mentioned, stage 4, when I read the paper, has more true positives likely based on or related to how much cell-free DNA is released in the tumor. The tumor burden may be playing a role there. Could you explain that a little more for our listeners? Dr. Eric Klein: A cancer that sheds cell-free DNA into the bloodstream is more likely to be aggressive, and that's been shown in multiple different studies using multiple different platforms. And the reason for that is that the ability to shed cell-free DNA into the bloodstream goes along with biologic processes that we know are related to tumor aggressiveness. So that's a higher mitotic rate, it's neovascularization or the angiogenic switch, it's the ability to be an invasive cancer. And so the fact that you can detect cell-free DNA in the bloodstream implies some degree of biologic aggressiveness, which is not to say that tumors that shed cell-free DNA into the bloodstream are not curable. They are, in fact, curable at the same rate as cancers in people who are not tested for cell-free DNA. We know that for sure. It's just a signal that is there for us to exploit for the detection of cancers in asymptomatic individuals. And the hope is when we screen the general population, the general asymptomatic population for cancer, as we do with mammography and colonoscopy and PSA and so forth, that we can detect cancers at earlier stages, when they are far easier to cure. So I mentioned in CCGA3 that the overall sensitivity across all stages for detecting the presence of known cancers was 51%. That varied from about 16% for stage 1 cancers to 40% for stage 2 cancers to over 80 and 90% for stage 3 and 4 cancers. Dr. Rafeh Naqash: Right. And again, to provide more background to this, what we've come to understand gradually, as you mentioned, is that shedding is an important event in cancer trajectory. Do you think detection of cancers that are likely positive, driver mutation positive, have a lesser tendency to shed and maybe resulting in lesser tendency to earlier detection also, or is that not something that's true?  Dr. Eric Klein: No, I don't think it has anything to do with the presence of driver mutations. The methylation signal that we see is a reflection of the perturbation of methylation in normal cells. So normal cells turn genes on and off using methylation. That's well known. Cancer cells exploit that biologic process of methylation by - in a gross oversimplification, but in a way that makes it understandable - they use methylation to turn off all the genes that prevent cell growth and turn on all the genes that allow cells to proliferate and get all these other biologic properties that make them invasive and so forth. So it's really important to understand that the test that was used in this study and that was developed in CCGA3 measures a shared cancer signal across multiple different cancer types. In CCGA3, we were able to detect more than 50 different individual kinds of cancers. It's a shared cancer signal that is fundamental to the biology of cancers, not just a specific cancer, but cancers.  Dr. Rafeh Naqash: I see. I think what I was trying to say, basically was, when we do liquid biopsies in the regular standard of care clinic, and you're trying to assess VAFs or variant allele frequencies for a certain mutation, you tend to see some of these BRAFs or EGFRs that are very low VAF, and the data that I've seen is that you treat irrespective of the low VAF, if it's a driving mutation process. If your VAF is 0.1%, you still treat it with a targeted inhibitor. The context that I was trying to put into this is it all depends on shedding. So this liquid biopsy that we currently use, whether other platforms that are out there, if you're not shedding as much cell-free DNA or circulating tumor DNA, you're probably not going to catch that subclone or clone that is a driver. So, does that play a role in your test also? If you have, let's say, a lung cancer that is an EGFR stage 4, if the shedding is low, following a general conceptual context that these driver mutation-positive tumors do have less shedding in general than the non-driver mutation-positive, would you think that would somehow impact the detection using your test or your approach? Dr. Eric Klein: So, generically speaking, any test that looks for a cancer signal in blood is going to have a lower limit of detection. So there are analytic variables that make it such that, if you have extremely low levels of cell-free DNA or your other target shed into the blood, it's not going to be detected by the test. That's an analytical issue. Having said that, it's important to distinguish the fact that this test that we're developing isn't really a liquid biopsy. A liquid biopsy, really, if you think about it, is on patients who have known cancer, and you're doing a biopsy of the blood to determine if you can see a signal in the blood. This test has been developed to screen asymptomatic individuals who are at elevated risk of cancer, who actually may not have cancer. So we don't really view it as a liquid biopsy. But conceptually, you are correct that every test is going to have an analytical lower limit of detection so that not every tumor that sheds minuscule amounts of cell-free DNA will be detected. But that's not really relevant to this particular paper, I would say. It's not really relevant to the performance characteristics that we saw in this population. Dr. Rafeh Naqash: Understood. Thank you for differentiating the usual liquid biopsy approach that we use currently in the clinic, and this approach, which is meant more for detection in asymptomatic individuals.  Going to some of the results, could you highlight some of the interesting findings that you had in this paper as far as performance is concerned? Dr. Eric Klein: Sure. Let me put it in a clinical context because we were just discussing asymptomatic individuals. That's what the test is ultimately meant for - screening asymptomatic individuals. But a common problem in oncology is this: patients present to primary care physicians with vague or nonspecific symptoms. Someone with COPD, for example, who presents with a cough, the cough could be due to the COPD, but if they have an underlying lung cancer, the cough could also be due to the lung cancer. Or someone presents with GI symptoms, could be related to cancer, or it could be related to a whole host of other things. And so there is a challenge for primary care physicians to sort out who might have cancer and who does not, particularly if they present with vague symptoms. In fact, most cancer diagnoses in the United States and Great Britain are actually found by primary care providers.   In this paper, we looked retrospectively, after the fact, in CCGA3, the case-control study that we did, to see how this methylation-based test performed in individuals who had symptoms that could be associated with cancer, or could be due to cancer, or might not be, might be due to other things. What we found was that the performance characteristics were as good or better in this symptomatic population, where the physician is facing a diagnostic dilemma, as they were in the asymptomatic population. This is really important, specificity false negative rate across all the patients in the study was the same as it was in CCGA3. It was 99.5%. Again, the false positive rate was only 0.5%. We found, however, that overall sensitivity was better in the symptomatic population, and it was 64% instead of, or as compared to 43% in the asymptomatic population. That is not surprising because some patients who present with symptoms are more likely to have cancer.   We also looked at a subset of patients who had GI cancers because that's a very, very common presenting symptom in primary care practice, and this test performs exceptionally well for detecting GI cancers. We found that the overall sensitivity was 84%. Finally, and importantly, in terms of the clinical utility of a blood-based test to detect cancer and direct a diagnostic workup, what we call the clinical signal origin accuracy - the likelihood or prediction that a positive signal was related to a particular tumor type - overall accuracy in this population was 90%. So if you had a cancer signal detected and you had a clinical signal of origin assigned to it, let's say, the test came back with cancer signal detected, the CSO prediction was GI cancer, the overall accuracy in actually finding a GI cancer was 90%. Actually, it was a little higher for GI cancers, but overall, for all cancers, it was 90%. Dr. Rafeh Naqash: You mentioned that GI cancers had a very high sensitivity, around 84% or so. Is that, again, related to the tumor shedding compared to some other tumor types?  Dr. Eric Klein: Yes, there is a broad range of shedding across tumor types. So if you look at our data from CCGA, cancers like thyroid, prostate, and kidney do not shed a lot of cell-free DNA into the bloodstream, whereas GI cancers, hematologic malignancies, ovarian and pancreatic cancers shed much more cell-free DNA, and therefore their sensitivity for detection of those cancers is better.  Dr. Rafeh Naqash: What would be the alternate approach? Your sensitivity here is 64%, which is pretty good, but it's not perfect. So the patients who potentially would be missed using this test, what would be the alternate approach capturing those patients also and hopefully avoiding a missed cancer diagnosis?  Dr. Eric Klein: Well, it would be whatever the standard workup is that a primary care physician orders for someone who has vague symptoms. So, he idea here was to develop this, what we call a diagnostic aid for cancer detection in the symptomatic population. The idea here is to make the workups more efficient and to lend a greater degree of certainty as to what the diagnostic pathway ought to be. So, if you have a patient with vague symptoms and you're not sure if they are due to cancer or not, you might order a pretty broad diagnostic evaluation that might not end up finding cancer. In fact, if you take all the patients in a primary care setting, only about 7% of those individuals have cancer. Whereas, if you have a blood test that has a sensitivity of 64% and a positive predictive value of 75%, and you did that blood test early in the diagnostic workup and it was positive, you can do a much more tailored and perhaps a more efficient evaluation in speeding the diagnostic resolution.  Dr. Rafeh Naqash: As you mentioned, perhaps avoid unnecessary testing, which adds to the overall cost burden in the healthcare field.   Dr. Eric Klein: Correct. This was tested in another study called SYMPLIFY, which was done in a similar population of patients as this study - symptomatic patients presenting with vague symptoms or GI symptoms or weight loss, fatigue, those sorts of things, to primary care practice in the UK. And that was a prospective study. And the performance characteristics were very similar to what we saw in this study, although the overall positive predictive value in that study was 75% if you look at all cancers. And that would be very useful to a primary care physician and a patient to know what the likelihood of their having cancer is at the time they present or within a few days of presenting. Dr. Rafeh Naqash: Absolutely. And perhaps, to complement this approach with some of the other diagnostic approaches, maybe the possibility of detecting cancer earlier increases. So this is likely complementary and not necessarily the one-stop-shop. Dr. Eric Klein: It's important to understand that even in the symptomatic population, this is a screening test. And so, like all screening tests, if you have a positive mammogram that shows a nodule, you need to have a diagnostic workup to prove whether or not you have cancer. This blood test does not make the diagnosis of cancer; it simply helps direct a diagnostic evaluation that's necessary to confirm whether or not cancer is present or absent. That's true for both the asymptomatic and symptomatic populations. Dr. Rafeh Naqash: Could you tell us a little bit more about the CSO prediction in the general context of oncology and NGS, or the whole transcriptome sequencing that we do these days? We often see on a report that says,“What is the likely tumor of origin?” if you have an unclear primary. Can you explain that in the context of the approach that you guys use for CSO prediction? How does it differ from methylation versus mRNA prediction of tumor of origin or cell of origin?  Dr. Eric Klein: Methylation has a rich signal in it, and it can distinguish cancer cells from a non-cancer signal, and using a second algorithm, specific methylation patterns that are specific to given lineages can identify lung cancer versus colon cancer versus liver cancer.  Dr. Rafeh Naqash: Understood. Do you see this as becoming an approach that could be used, using, for example, urine or other sources that we can easily acquire versus blood? Dr. Eric Klein: Possibly. There is a lot of work in the field looking at urine-based markers for cancers, particularly, obviously, urologic cancers. And so there are already some products on the market made by other companies using methylation and other specific mutation patterns, for example, in urine to detect bladder cancer and to determine bladder cancer aggressiveness. It is an area of active investigation.  Dr. Rafeh Naqash: This is definitely an exciting field, and the way the entire field of liquid biopsies in general is moving as it's detecting cancers or identifying mutations, and then implementing appropriate approaches, whether it is more screening or more treatment and all the drugs, etc.  Are there any other interesting future approaches that you guys are planning as part of this paradigm shift that I envision will hopefully happen in the next few years?  Dr. Eric Klein: Yes, as a company, Grail is focused on using this methylation-based technology across the entire cancer spectrum. So that's screening asymptomatic individuals, it's helping to direct diagnostic workups in individuals who present with symptoms to primary care practice, and also in the post-diagnostic space and all the possible uses there. So the detection of minimal residual disease and the decision on whether or not additional treatment is necessary, predicting response to particular therapeutic agents, or even choosing the correct therapeutic agents. All of that is under development. Dr. Rafeh Naqash: Definitely exciting. Now, the last portion of this podcast is specifically meant to highlight your career and know a little bit more about you. Could you tell us about your career trajectory and how you shifted focus towards a biomarker-driven approach?  Dr. Eric Klein: Sure. Biomarkers have been a part of my career for a long time. I am trained as a urologic oncologist and did my residency in urology at the Cleveland Clinic and a fellowship at Sloan Kettering. At the dawn of the molecular biology era, the lab I worked in bought one of the very first PerkinElmer RT PCR machines for $5,000. It took up a whole desktop. I got very interested in genomic science at that time. So I spent well over 30 years practicing urologic oncology at the Cleveland Clinic, primarily focusing on prostate cancer. In the course of my career, I had the opportunity to work on a number of blood-based, urine, and tissue-based biomarkers. I have always been interested in understanding how our ability to measure molecules in blood and urine can help improve patient outcomes either through a streamlined diagnostic process or understanding of the biology of the disease better, picking the appropriate therapy, and so forth.  In the course of that, I worked with someone at a company called Genomic Health in developing  a biopsy-based RT PCR gene expression assay that helped select men for active surveillance. That individual subsequently joined Grail and he came knocking on my door in 2016 when Grail was just getting started to tell me about this exciting new technology. He said, “This isn't about urologic cancers in particular, but would you be interested in helping us accrue patients for this big clinical trial we're doing, CCGA, and determine if this technology would be useful in some way in helping patients.” And being the curious individual that I am, I said, “Sure.” And so I helped accrue lots of patients to CCGA. The results were shared, and I was quite excited by them and continued to work with the company on other studies, including PATHFINDER and some others, and eventually became a consultant for them.  When I reached what I thought was the end of my clinical career by choice, I decided to step away from clinical practice, I had the opportunity to join Grail as a scientist, and that's where it's been. And what I would say, in the big picture, is this: as a surgeon, I was able to help a lot of patients on an individual basis. So I did about 10,000 major cancer operations in my career. So I helped those 10,000 people. As an academician, I was able to make certain observations and publish them in a way that taught people about different kinds of surgical techniques and how they may work better, and so I was able to expand my impact beyond the patients that I actually touched.  When I heard about and understood what Grail was trying to do, I thought, “Wow, if we could develop a screening test that detects lots of cancers that we don't screen for - about 70% of all cancer deaths in the US are from cancers that we have no screening tests for - and if the screening population in the United States, individuals between ages 50 and 79, that's how CMS defined screening populations, well over 100 million a year, if this works, think about the impact that that could have.” That is really why I got excited about it. It fit my scientific interest, and I could see the big picture.  Dr. Rafeh Naqash: Thank you for giving us some insights about your personal career. It is definitely a very interesting topic. I learned a lot, and hopefully, our listeners will find it equally interesting. Thank you again for being here today.  Dr. Eric Klein: My pleasure. Thank you for having me. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to rate and review this podcast, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and inform. It is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   The guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not reflect the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.        

What should rheumatologists know about what we've learned about COVID-19 and long COVID in 2023? Hosted by Dr. Leonard Calabrese. ·       Intro 0:11 ·       In this episode 0:21 ·       2023: current status and controversies 0:35 ·       What is going on with COVID-19? 01:53 ·       What do we know about vaccine responses? What should we be telling our patients about vaccines in our immunocompromised population? 2:58 ·       Lancet Rheumatology MELODY study summary 3:08 ·       What about patients within the rheumatic and autoimmune disease space? 4:15 ·       Who is immunocompromised and why does it matter? 5:11 ·       What is the immunosuppression we are giving them? 6:39 ·       What to tell patients about getting vaccinated 8:56 ·       Long COVID 10:09 ·       What is long COVID? 10:26 ·       JAMA Network Open study on prevalence and characteristics associated with post-COVID conditions 14:19 ·       In the clinical arena, what should rheumatologists be thinking about? 16:38 ·       What about pathogenesis? What do we know about the controversies in this area? 18:58 ·       Autoimmunity: COVID-19 and autoimmune response 20:45 ·       What about therapies? 22:22 ·       The next generation of rheum agents: Immunomodulation with neonatal Fc receptor targeting? 24:40 ·       A question for the rheumatology community: do patients with immune mediated diseases get more long COVID than the control population? 25:40 ·       In conclusion 27:37 ·       Thanks for listening 28:38 Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic. Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB.. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.

Get Free Weekly Health Tips from Dr. HymanSign Up for Dr. Hyman's Weekly Longevity JournalGet Ad-free Episodes & Dr. Hyman+ Audio ExclusivesThe foundation of our health is a robust immune system that has a very important mechanism of cleaning out inflammatory cells. If this process is broken, the inflammatory cells can actually turn other functioning cells into inflammatory cells. Our daily life habits and exposures, such as sleep, stress management, diet, and toxins, affect key biological processes that impact our immune function. When our immune health is functioning properly, the rest of our body follows with less illness and disease.In today's episode, I talk with Dr. Elizabeth Boham and Dr. Leonard Calabrese about ways that we can support our immune systems to reduce the chance of illness and disease.Dr. Elizabeth Boham is a physician and nutritionist who practices Functional Medicine at The UltraWellness Center in Lenox, MA. Through her practice and lecturing she has helped thousands of people achieve their goals of optimum health and wellness. She witnesses the power of nutrition every day in her practice and is committed to training other physicians to utilize nutrition in healing.Dr. Leonard Calabrese is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Vice Chair of the Department of Rheumatic and Immunologic Diseases. He is also the director of the RJ Fasenmyer Center for Clinical Immunology at the Cleveland Clinic and holds joint appointments in the Department of Infectious Diseases and the Wellness Institute.This episode is brought to you by Rupa University, AG1, and Paleovalley.Rupa University is hosting FREE classes and bootcamps for healthcare providers who want to learn more about Functional Medicine testing. Sign up at RupaUniversity.com.Get your daily serving of vitamins, minerals, adaptogens, and more with AG1. Head to DrinkAG1.com/Hyman and get 10 FREE travel packs with your first order.Paleovalley is giving listeners an additional 15% off their first order. Just visit Paleovalley.com/Hyman to save on clean snacks and supplements.Full-length episodes of these interviews can be found here:Dr. Mark HymanDr. Elizabeth BohamDr. Leonard Calabrese Hosted on Acast. See acast.com/privacy for more information.

Interviewees:  Cleveland Clinic Group - Craig Nielsen MD (Clinical Leadership), Stacie Jhaveri MD,  Diane Young MD (OB-GYN clerkship), Theresa Papich (4th year medical student). Description: This is a story about what happens when everything goes well and when creativity and a can do attitude lead the discussion. Today, we are talking with a team of OB-GYN clerkship, residency and clinical leaders from Case Western Reserve University and the Cleveland Clinic Lerner College of Medicine, and Theresa Papich, a 4th year medical school student who is a wheelchair user. Throughout our conversation we discuss the accommodations employed to create equal access and the lessons learned along the way.  Most importantly we'll talk with Theresa about how this experience felt for her and what she believes schools can do to improve access for learners with disabilities. Transcript: https://bit.ly/DWDI_Podcast_Ep79 Produced by: Lisa Meeks and Tamar Faggen Audio editor: Jacob Freeman Digital Media: Katie Sullivan Keywords: medical education, disability representation, doctors with disabilities, accessibility, disability mentorship, OB-GYN, clerkship, disability inclusion, wheelchair user, clinical accommodations, internal medicine Website: https://www.docswithdisabilities.org/podcast    

Today we get to talk about the gut and skin "picture" that tends to show up in psoriasis patients. There's research that states that the gut of those who have psoriasis looks eerily similar to those who have inflammatory bowel disease or IBD. Yikes! Today's guest completely agrees with the emerging research as well, so let's dive in. Today's guest is Fabrizio Galimberti. He completed his medical training at Cleveland Clinic Lerner College of Medicine-Case Western Reserve University, received his doctorate degree from Dartmouth College and his residency at the Jackson Memorial Hospital-University of Miami Miller School of Medicine where he also served as chief resident. Dr. Galimberti's research interests include oncodermatology, autoimmune connective tissue diseases, and impact on quality of life of dermatologic conditions. He has published numerous articles in prestigious journals as well as presented his work at international conferences. Are you a psoriasis warrior? How have you managed psoriasis? Let me know in the comments below! In this episode: Why psoriasis is NOT just a skin condition What does someone with psoriasis have in common with someone who has IBD or Crohns? Insight on looking at spouses who have the SAME diet where one has psoriasis and the other doesn't Why gut variability is important and how you CAN alter it Strep and other viruses as a possible trigger Quotes "It is a systemic disease. You see psoriasis, but psoriasis does not start on the skin. It starts inside your body." [01:15] "We do know that strep particularly can cause (a flare), but there's quite a lot of data out there that also suggests, for example, HPV or human papilloma virus, may be related to that." [21:47] Links Dr. Galimberti can be found at this email address: fxg331@med.miami.edu Healthy Skin Show ep. 069: Is Psoriasis A Gut Problem? Healthy Skin Show ep 117: Can A Strep Infection Trigger Psoriasis? Healthy Skin Show ep. 238: Inflammatory Connection Between Psoriasis + Depression w/ Fabrizio Galimberti, MD, PhD

Do you know your genetic risk for breast cancer?  It is more than a BRCA test and we are reintroducing Dr. Holly Pederson's episode to explain the research. Dr. Pederson is the Medical Director for Breast Services at Cleveland Clinic and an Associate Professor at at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.  She explains: *genetic risk assessments including the new Polygenic Risk Score, *which breast exams are right for different patients: digital mammogram, 3D mammogram, ultrasound or the abbreviate MRI * when it is appropriate to use preventative measures prior to a diagnosis of breast cancer. Show Notes: www.hotflashescooltopics.com Information for our CONVERSATIONS WITH PRIME WOMEN event on October 8 at the Nashville Graduate Hotel can be found: www.conversationswithprimewomen.com FOLLOW US ON: Instagram: https://www.instagram.com/hotflashesandcooltopics/ Youtube: https://www.youtube.com/channel/UC6ssWfO0qeZYEIs6TzrKBHQ Facebook: https://www.facebook.com/groups/657557054765087   Want to Leave a Review for Hot Flashes and Cool Topics? Here's How: For Apple Podcasts on an iPhone or iOS device: Open the Apple Podcast App on your device. Click on the “search” icon Type into the search bar “Hot Flashes and Cool Topics” and click on the show Towards the bottom, look for “Ratings and Reviews” Click on “Write a Review” and leave us your thoughts and comments! For Apple Podcasts on a computer: On the Apple Podcasts website, go to the search bar and type “Hot Flashes and Cool Topics” After clicking on the show, find the “Listen on Apple Podcasts” button and click on it The “Hot Flashes and Cool Topics” podcast should open on the Apple Podcasts application Keep scrolling on the page until you see “Ratings and Reviews” Click on “See All” If you want to give us a five-star rating, hover over the empty stars! If you want to leave your thoughts and comments, click on “Write a Review”! *

In this episode, we speak with medical student James Sullivan from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University about the process of creating an integrated climate-health curriculum at the medical school. If you want to learn more, check out this journal article about the Cleveland Clinic's climate-health curricular design: 10.1097/ACM.0000000000004376 Episode written by Genny Silva, Produced by Natasha Sood, and Edited by Liana Haigis

In this week's episode of the Neurophilia Podcast, we discussed the relationship between Neurology and Palliative Medicine, the need for empathy and vulnerability in patient conversations, the emerging field of Neuropalliative Medicine, how to celebrate the small victories in medicine, and even Dua Lipa! In this episode, we are joined by Dr. Kathleen Neuendorf and Dr. Renato Samala.Dr. Kathleen Neuendorf, MD has been a palliative medicine physician, working primarily as a consultant in the hospital, since 2010. She was drawn to the field because it brought an honesty and clarity that people seemed to need but weren't always getting. Dr. Neuendorf is known both locally and nationally for her work in relationship-centered communication and leadership. Outside of work, she is a proud mom of 3, enjoys spending time with her husband and taking walks in the Metroparks.Dr. Renato V. Samala, MD is a staff physician in the Department of Palliative and Supportive Care at the Taussig Cancer Center, and an Associate Professor of Medicine at Cleveland Clinic Lerner College of Medicine. After graduating from the University of the Philippines College of Medicine, he completed a residency in internal medicine at UPMC McKeesport, and fellowships in Geriatrics and Hospice and Palliative Medicine at Cleveland Clinic. Dr. Samala is a fellow of the American College of Physicians and the American Academy of Hospice and Palliative Medicine. He has written numerous articles published in peer-reviewed journals and textbooks, and has presented at local, national and international conferences.References:Boersma, I., Miyasaki, J., Kutner, J., & Kluger, B. (2014). Palliative care and neurology: Time for a paradigm shift. Neurology, 83(6), 561–567. https://doi.org/10.1212/wnl.0000000000000674 Brizzi, K., & Creutzfeldt, C. (2018). Neuropalliative care: A practical guide for the neurologist. Seminars in Neurology, 38(05), 569–575. https://doi.org/10.1055/s-0038-1668074 Creutzfeldt, C. J., Robinson, M. T., & Holloway, R. G. (2016). Neurologists as primary palliative care providers. Neurology: Clinical Practice, 6(1), 40–48. https://doi.org/10.1212/cpj.0000000000000213 Silveira, M. R., & Forte, D. N. (2022). Palliative care and neurology: A path to neuropalliativism. Arquivos de Neuro-Psiquiatria, 80(5 suppl 1), 328–335. https://doi.org/10.1590/0004-282x-anp-2022-s119 Taylor, L. P., Besbris, J. M., Graf, W. D., Rubin, M. A., Cruz-Flores, S., & Epstein, L. G. (2022). Clinical guidance in neuropalliative care. Neurology, 98(10), 409–416. https://doi.org/10.1212/wnl.0000000000200063 Zehm, A., Hazeltine, A. M., Greer, J. A., Traeger, L., Nelson-Lowe, M., Brizzi, K., & Jacobsen, J. (2019). Neurology clinicians' views on Palliative Care Communication. Neurology: Clinical Practice, 10(6), 527–534. https://doi.org/10.1212/cpj.0000000000000794 Support the show

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at the 75th American Academy of Neurology Annual Meeting, held April 22-27, 2023, in Boston, Massachusetts. Those included in this week's episode, in order of appearance, are: Michael H. Barnett, MBBS, PhD, FRACP, a consultant neurologist at Royal Prince Alfred Hospital (RPAH) Sydney, director of the RPAH MS Clinic and the MS Clinical Trials Unit at the Brain and Mind Centre; codirector of the MS Research Australia Brain Bank; and a senior professor at the University of Sydney. Nancy R. Foldvary-Schaefer, DO, FAAN, the director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic, and a professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Sean J. Pittock, MD, the director of the Center for Multiple Sclerosis and Autoimmune Neurology and director of the Neuroimmunology Research Laboratory at Mayo Clinic. Katherine W. Turk, MD, a neurologist at Boston VA Memory Disorders Clinic, principal investigator and codirector of the Center for Translational Cognitive Neuroscience lab (CTCN) at VA Boston; and assistant professor of neurology and coleader of the Outreach, Recruitment and Engagement core of the Alzheimer's Disease Research Center at Boston University. Erika U. Augustine, MD, MS, the associate chief science officer and director of the Clinical Trials Unit at the Kennedy Krieger Institute. Jeffrey M. Statland, MD, a neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center. Chian-Chun Chiang, MD, a stroke and migraine specialist and assistant professor of neurology at Mayo Clinic. Want more from the 75th American Academy of Neurology Annual Meeting? Click here for all of NeurologyLive®'s coverage of AAN 2023. Episode Breakdown: 1:10 – Barnett on the topline findings for CNM-Au8 from the VISIONARY-MS clinical trial. 8:35 – Foldvary-Schaefer on the understanding of the relationship between epilepsy and sleep. 13:25 – Pittock on the latest data on ravulizumab from the CHAMPION-NMOSD trial. 19:00 – Turk on the landscape of diagnosis and treatment for mild cognitive impairment, and how to improve the process. 22:00 – Augustine on Dr. Sidney Carter and the current paradigm of care in child neurology. 27:15 – Statland on the findings for ataluren in nonsense mutation Duchenne muscular dystrophy from Study 041. 34:05 – Chiang on the takeaways from a big data analysis of 25 therapies for acute migraine management. This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Barnett MH. VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 2. Foldvary-Schaefer NR. Diagnostic Testing: Beyond the MSLT. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 3. Pittock SJ. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 4. Statland JM. Safety and Efficacy of Ataluren in nmDMD Patients from Study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 5. Chiang CC. Simultaneous Comparisons of 25 Acute Migraine Medications: A Big Data Analysis of 10 Million Patient Self-Reported Treatment Records From A Migraine Smartphone Application. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA.

“Neurology is closer to internal medicine than any other specialty. Justifiably, neurologists are reverting back to their role as internists of the nervous system”-Jose Biller. In this episode of the Neurophilia Podcast, we discuss the relationship between neurology and medicine, how to improve communication between primary and secondary care, specialization in medicine, what makes a "good consult," and the importance of patient advocacy in all fields of medicine. We are joined by Neurophilia Co-host, Dr. Blake Buletko, and two very special guests, Dr. Deborah Plate and Dr. Austin Fredrickson. #dailyneurologyuplifters Dr. Blake Buletko is a vascular neurologist at the Cleveland Clinic. He completed his residency and fellowship training at the Cleveland Clinic and was the former medical director of their mobile stroke program. In addition to his clinical responsibilities, Dr. Buletko serves as an Assistant Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is the current Program Director of the Adult Neurology Residency program for the Cleveland Clinic.Dr. Deborah Plate is a board-certified Family Medicine Physician. She is currently the Chair and Clinical Associate Director at the Center for Family Medicine residency program at Cleveland Clinical Akron General. She has a private practice at CFM and loves caring for her patients, some of whom she has cared for 30 years. Dr. Austin Fredrickson is an associate professor of internal medicine at NEOMED and a board-certified general internist practicing primary care in his hometown of Salem, Ohio. He serves in medical leadership positions at the state and national levels, and is currently his county's deputy coroner, although Dr. Fredrickson's greatest claim to fame may be that he was a pupil of the infamous Dr. Deborah Plate. References:Aminoff, M. (n.d.). Neurology is not enough - aan.com. Neurology is Not Enough. Retrieved March 30, 2023, from https://www.aan.com/globals/axon/assets/4570.pdf Lanska DJ. The Interface of Neurology & Internal Medicine. JAMA. 2008;299(8):960–961. doi:10.1001/jama.299.8.960Majersik JJ, Ahmed A, Chen IA, Shill H, Hanes GP, Pelak VS, Hopp JL, Omuro A, Kluger B, Leslie-Mazwi T. A Shortage of Neurologists We Must Act Now: A Report From the AAN 2019 Transforming Leaders Program. Neurology. 2021 Apr 30:10.1212/WNL.0000000000012111. doi: 10.1212/WNL.0000000000012111. Epub ahead of print. PMID: 33931527.Morrish P. The changing relationship between neurology and general practice in the UK. Br J Gen Pract. 2009 Aug;59(565):599-604. doi: 10.3399/bjgp09X453837. PMID: 22751237; PMCID: PMC2714785.Murray TJ. What should a family physician know about neurology? Can Fam Physician. 1990 Feb;36:297-9. PMID: 21234042; PMCID: PMC2280633.Sanky, C., Gentile, C., Ren, J., Bortnick, E., & Krieger, S. (2023). Education research: The inappropriate consult. Neurology: Education, 2(1). https://doi.org/10.1212/ne9.0000000000200044 Swarztrauber K, Vickrey BG. Do neurologists and primary care physicians agree on the extent of specialty involvement of patients referred to neurologists? J Gen Intern Med. 2004 Jun;19(6):654-61. doi: 10.1111/j.1525-1497.2004.30535.x. PMID: 15209604; PMCID: PMC1492387.Support the show

In this week's episode of the Neurophilia Podcast, we discuss the dynamic relationship of "Neurology and Neurosurgery;" including the proximal and respectful collaboration between these two fields of medicine, and areas of interdisciplinary training available at the resident level. Additionally, some time is spent discussing imposter syndrome in medicine and the growing need for women and minorities in the fields of neurology and neurosurgery. Come learn about neurology and neurosurgery as our guests, Dr. Blake Buletko and Dr. Julie Chen, share personal and professional anecdotes from their lives. Dr. Blake Buletko is a vascular neurologist at the Cleveland Clinic. He completed his residency and fellowship training at the Cleveland Clinic and was the former medical director of their mobile stroke program. In addition to his clinical responsibilities, Dr. Buletko serves as an Assistant Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is the current Program Director of the Adult Neurology Residency program for the Cleveland Clinic.Dr. Julie Chen is a pediatric neurosurgeon who completed her neurosurgery residency and epilepsy surgery fellowship at the Cleveland Clinic followed by a pediatric neurosurgery fellowship at the prestigious Children's Hospital of Philadelphia. Dr. Chen currently serves as the Director of Pediatric Neurosurgery at Akron Children's Hospital in Akron, Ohio. References: Bone I, Fuller G. NEUROSURGERY AND THE NEUROLOGIST. Journal of Neurology, Neurosurgery & Psychiatry 2002;73:i1-i2.Support the show

On this episode of My Lupus Living Room, Adrienne fills in for Suzanne and sits down with Dr Emily Littlejohn, DO, MPH from the Cleveland Clinic. She may be our most accomplished guest yet, and while she did complete her Rheumatology Fellowship at that school up north, she's made up for it in spades by helping countless lupus patients across Ohio. We've put her resume below: Emily Littlejohn completed her undergraduate education at Georgetown University, where she received a B.S in Human Science. After college she moved to Boston where she received a M.P.H in Epidemiology from Boston University of Public Health. She then attended Medical School at Western University College of Osteopathic Medicine of the Pacific (COMP) where she was awarded a research fellowship in the Department of Biotechnology. She went on to complete her Internal Medicine Residency at Loyola University Medical Center in Chicago, IL and Rheumatology Fellowship at the University of Michigan where she worked closely with lupus patients and became interested in this complex and elusive disease. She joined the medical staff in the Department of Rheumatic and Immunologic Diseases at Cleveland Clinic in 2017 and holds a faculty position of Clinical Assistant Professor in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. She directs the Cleveland Clinic Lupus Cohort (CCLC), a longitudinal bio repository that banks blood and urine of lupus patients and is co- director of the Lupus Clinic.

The term Neuropsychiatry refers to the "field of scientific medicine that concerns itself with the complex relationship between human behavior and brain function, and endeavors to understand abnormal behavior and behavioral disorders on the basis of an interaction of neurobiological and psychological–social factors."In this episode of the Neurophilia Podcast, we discuss the relationship between the mind and brain, or Neurology and Psychiatry. We also provide an in-depth review of overlapping pathologies, compare the clinical approaches of a neurologist and psychiatrist, and comment on the degree of interdisciplinary training available at the residency level. In this episode we feature Drs. Blake Buletko and Randon Welton. Dr. Blake Buletko is a vascular neurologist at the Cleveland Clinic. He completed his residency and fellowship training at the Cleveland Clinic and was the former medical director of their mobile stroke program. In addition to his clinical responsibilities, Dr. Buletko serves as an Assistant Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is the current Program Director of the Adult Neurology Residency program for the Cleveland Clinic.Dr. Randon Welton is currently the Margaret Clark Morgan Professor and Chair of Psychiatry at the Northeast Ohio Medical University (NEOMED) and the President of the American Association of Directors of Psychiatry Residency Training.  Before arriving at NEOMED, Dr. Welton has had a long career as both a military psychiatrist and psychiatric educator with a focus on psychotherapy and addressing the impact of trauma on mental health. References:Alsaadi, T., Kassie, S., Mohamed Ali, O., Mozahem, K., Al Fardan, S., & Ahmed, A. M. (2019, April 25). Psychiatric comorbidity in neurological disorders: Towards a multidisciplinary approach to illness management in the United Arab Emirates. Frontiers in psychiatry. Butler, C. (2005). Neurological syndromes which can be mistaken for psychiatric conditions. Journal of Neurology, Neurosurgery & Psychiatry, 76(suppl_1), i31–i38. Keshavan, M. S., Price, B. H., & Martin, J. B. (2020). The convergence of neurology and psychiatry. JAMA, 324(6), 554.Martin, J. B. (2002). The integration of neurology, psychiatry, and Neuroscience in the 21st Century. American Journal of Psychiatry, 159(5), 695–704. Sachdev, P. S., & Mohan, A. (2013). Neuropsychiatry: Where are we and where do we go from here? Mens Sana Monographs, 11(1), 4. Verghese, A. (2016). The integration of psychiatry and neurology. Indian journal of psychiatry. Williams, S. S. (2016). The terrorist inside my husband's brain. Neurology, 87(13), 1308–1311. Support the show

Kendalle Cobb, MD, is a board-certified Family Physician at Cleveland Clinic with an interest in health maintenance and disease prevention and adolescent health. She is Clinical Associate Professor of Medicine at Cleveland Clinic Lerner College of Medicine and is currently serving as an Associate Chief of Staff with a focus on recruitment and retention of physicians and scientists, particularly those traditionally underrepresented in medicine. Growing up in San Francisco, she studied ballet and when sidelined with an injury started thinking about other career options and ultimately went to medical school after receiving a BA in history from Harvard University. In this conversation, she talks about working with medical students, mentoring and supporting their challenges on their journeys to become doctors and the courage to ask for help and building a culture of psychological safety.

“The complementary—and some would say—diametrically opposite—clinical methods of the dermatologist and the neurologist can in these circumstances reduce an otherwise dauntingly large differential into a more tractable, smaller list.” In this episode of the Neurophilia Podcast, we discuss the fascinating relationship between Neurology and Dermatology, review the various pathologies shared between these two systems, and highlight the art of medicine between two specialists, Dr. Blake Buletko and Dr. Eliot Mostow. Dr. Blake Buletko is a vascular neurologist at the Cleveland Clinic. He completed his residency and fellowship training at the Cleveland Clinic and was the former medical director of their mobile stroke program. In addition to his clinical responsibilities, Dr. Buletko serves as an Assistant Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is the current Program Director of the Adult Neurology Residency program for the Cleveland Clinic.Dr. Eliot Mostow is the Professor and Chair of the Dermatology Section at Northeast Ohio Medical University. He is the President of Akron Dermatology and has served the Akron Ohio community for nearly 30 years. He is extremely passionate about excellence in medical education, prevention of errors in medicine, and medical ethics. References:Basavaraj, K. H., Navya, M. A., & Rashmi, R. (2010, July). Relevance of psychiatry in dermatology: Present concepts. Indian journal of psychiatry. Retrieved February 18, 2023, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990831/ Hurko, O., & Provost, T. T. (1999). Neurology and the skin. Journal of Neurology, Neurosurgery & Psychiatry, 66(4), 417–430. https://doi.org/10.1136/jnnp.66.4.417 Neau, J.-P., Godeneche, G., Mathis, S., & Guillet, G. (2014). Neurodermatology. Handbook of Clinical Neurology, 1561–1594. Shah, P., Sagar, P. R., Alhumaidi, N., Bollampally, V. C., & Malik, B. H. (2020, August 22). Parkinson's disease and its dermatological associations: Is your skin whispering you a diagnosis? Cureus. Retrieved February 18, 2023, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505647/ Skin signs of neurological diseases. DermNet. (n.d.). Retrieved February 18, 2023, from https://dermnetnz.org/topics/skin-signs-of-neurological-diseases Support the show

Dr. Kevin Hopkins has been a Staff Physician in the Department of Family Medicine at the Cleveland Clinic since 2005.  Dr. Hopkins also serves as Primary Care Medical Director for Cleveland Clinic Community Care, the Cleveland Clinic's primary care, population health institute.  Over the past several years he has become a recognized leader and national speaker in the field of Caregiver burnout and ambulatory practice re-design and transformation.  Dr. Hopkins has led the transition of his primary care group to a model of Value-Based Care and is continuing to leverage an advanced team-based care practice model as a vehicle to achieve the goals of population management.  He holds an academic appointment with Cleveland Clinic Lerner College of Medicine as a Clinical Assistant Professor in the Department of Family Medicine, teaches within the Cleveland Clinic Family Medicine Residency Program, and is also a faculty instructor for the Cleveland Clinic Global Leadership and Learning Institute.  Dr. Hopkins is a Senior Physician Advisor with the Professional Satisfaction and Practice Sustainability Initiative for the American Medical Association (AMA) and has previously served as a physician advisor for Google Health.Thanks for tuning in! Check out more episodes of The Well-Being Connector Podcast at www.forphysicianwellbeing.org/podcast.

Parallax features a guest episode from the new podcast Neurophilia by Nupur Goel. Do you think and act with your mind or heart? How about both? Neurocardiology refers to the intersection between the fields of neurology and cardiology. The mind and heart are deeply interconnected in terms of anatomy, physiology, and various pathologic states. This episode features a vascular neurologist and an interventional cardiologist who will discuss the relationship between their two fields of medicine. Dr. Blake Buletko is a vascular neurologist at the Cleveland Clinic. He completed his residency and fellowship training at the Cleveland Clinic and was the former medical director of their mobile stroke program. In addition to his clinical responsibilities, Dr. Buletko serves as an Assistant Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is the current Program Director of the Adult Neurology Residency program for the Cleveland Clinic. Dr. Ankur Kalra is an interventional cardiologist, and founder of the non-profit startup, makeadent.org. He is director of Barry J. Maron Hypertrophic Cardiomyopathy Center in New Delhi, India. He is also the host of the cardiology podcast show, Parallax. He has presented late-breaking science at national and international scientific cardiovascular meetings, and has published over 250 scientific manuscripts in various peer-reviewed journals. His past appointments include interventional cardiologist, associate professor, and medical director of clinical research for regional cardiovascular medicine at the Cleveland Clinic. Check out the Neurophilia podcast by Dr Nupur Goel: https://podcasts.apple.com/gb/podcast/neurophilia/id1654775116

Do you think and act with your mind or heart? How about both?Neurocardiology refers to the intersection between the fields of neurology and cardiology. The mind and heart are deeply interconnected in terms of anatomy, physiology, and various pathologic states. This episode features a vascular neurologist and an interventional cardiologist who will discuss the relationship between their two fields of medicine.Dr. Blake Buletko is a vascular neurologist at the Cleveland Clinic. He completed his residency and fellowship training at the Cleveland Clinic and was the former medical director of their mobile stroke program. In addition to his clinical responsibilities, Dr. Buletko serves as an Assistant Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is the current Program Director of the Adult Neurology Residency program for the Cleveland Clinic.Dr. Ankur Kalra is an interventional cardiologist, and founder of the non-profit startup, makeadent.org. He is director of Barry J. Maron Hypertrophic Cardiomyopathy Center in New Delhi, India. He is also the host of the cardiology podcast show, Parallax. He has presented late-breaking science at national and international scientific cardiovascular meetings, and has published over 250 scientific manuscripts in various peer-reviewed journals. His past appointments include interventional cardiologist, associate professor, and medical director of clinical research for regional cardiovascular medicine at the Cleveland Clinic.Studies mentioned in this episode:Goldstein LB, El Husseini N. Neurología y cardiología: puntos de contacto [Neurology and cardiology: points of contact]. Rev Esp Cardiol. 2011 Apr;64(4):319-27. Spanish. doi: 10.1016/j.recesp.2010.12.004. Epub 2011 Mar 15. PMID: 21411208.Gottesman RF, McKhann GM, Hogue CW. Neurological complications of cardiac surgery. Semin Neurol. 2008 Nov;28(5):703-15. doi: 10.1055/s-0028-1105973. Epub 2008 Dec 29. PMID: 19115176; PMCID: PMC5607742.Jabri A, Kalra A, Kumar A, et al. Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020;3(7):e2014780. doi:10.1001/jamanetworkopen.2020.14780Lacerte M, Hays Shapshak A, Mesfin FB. Hypoxic Brain Injury. [Updated 2022 Nov 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537310/Oppenheimer SM, Lima J. Neurology and the heart. Journal of Neurology, Neurosurgery & Psychiatry 1998;64:289-297.Samuels, M. A. (2007). The brain–heart connection. Circulation, 116(1), 77–84. https://doi.org/10.1161/circulationaha.106.678995 Sherman, D. G., Hart, R. G., & Shi, F. (1987). Heart-brain interactions: Neurocardiology or cardioneurology comes of age. Mayo Clinic Proceedings, 62(12), 1158–1160. https://doi.org/10.1016/s0025-6196(12)62513-0 Wang X, Pei J, Hu X. The Brain-Heart Connection in Takotsubo Syndrome: The Central Nervous System, Sympathetic Nervous System, and Catecholamine Overload. Cardiol Res Pract. 2020 Mar 9;2020:4150291. doi: 10.1155/2020/4150291. PMID: 32211202; PMCID: PMC7085406.Support the show

Dr. José L. Navia is the Director of the Heart and Vascular Center at Cleveland Clinic Florida, Chairman of Cardiothoracic Surgery in Florida, and a Distinguished Chair in Heart and Vascular Research. Dr. Navia is also a Professor of Surgery at Cleveland Clinic Lerner College of Medicine and an internationally known cardiovascular and thoracic surgeon. With 30 patents to his name, Dr. Navia has made numerous advances in cardiovascular medicine. Today, Dr. Navia joins us on the Health Pulse podcast to speak on a particularly special past case of his, as well as his passion and drive for innovation.

Neurophobia, or the "fear of clinical neurology amongst medical students and resident doctors," is a widely known and accepted phenomenon within the medical community. This podcast will provide an overview of the history and prevalence of the term,  followed by an engaging discussion, between three Neurologists, about tackling the growing issue of Neurophobia. In this episode, we will feature Drs. Blake Buletko, Ahmed Itrat, and Michael Kentris.Dr. Blake Buletko is a vascular neurologist at the Cleveland Clinic. He completed his residency and fellowship training at the Cleveland Clinic and was the former medical director of their mobile stroke program. In addition to his clinical responsibilities, Dr. Buletko serves as an Assistant Professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is the current Program Director of the Adult Neurology Residency program for the Cleveland Clinic.Dr. Itrat graduated from the Aga Khan University of Health Sciences in Pakistan, followed by his neurology residency training, and vascular neurology fellowship at the Cleveland Clinic which he completed in 2015. He is currently a staff neurologist with the Cleveland Clinic and serves as a medical director of stroke at Cleveland Clinic Akron General, along with serving as the lead for neurology education. His interests include clinical research on stroke mechanisms, as well as quality improvement initiatives for stroke. Dr. Michael Kentris is a neurologist in Youngstown, OH. He completed residency at Wright State University and a clinical neurophysiology fellowship at Vanderbilt University. He has helped develop and been one of the primary narrators for the journal Continuum's "Read Aloud" program as well as recording his own medical education-themed podcast, "The Neurotransmitters.”The Neurophilia Podcast is hosted by Nupur Goel, a fourth-year medical student at Northeast Ohio Medical University.Support the show

In this episode, host Shikha Jain, MD, speaks with Michael Roizen, MD, author and chief wellness officer at the Cleveland Clinic, about developing tools that can help lead to a longer life, public health messaging in media and more. Welcome to another exciting episode of Oncology Overdrive :14 About Roizen :20 The interview 1:01 How did you get to where you are today, and what was your journey into medicine, health care and everything you are doing outside of clinical medicine? 1:30 How do we de-age ourselves, and what do we do to reboot ourselves? 4:30 Why have we not had a national movement toward this when this is something that many people care so much about? 9:39 Jain and Roizen on retirement age, life expectancy and medical benefits 11:38 Do you think there are any modifications or anything we should think about differently now that COVID is a part of our everyday life? 17:34 What are you covering in this book [The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow]? What is its purpose? 19:43 For those of us who are parents, does it matter if you start programming cells from a young age, or is this more for adults? 22:50 How did you get an Emmy? 27:12 What do you think of how communication to the public has changed? … What do you think about where we are going and how things have evolved over the years? 29:08 What's next for you? … How do you find the time to do all of this? 32:38 About Jain's non-profits and Roizen's involvement in gender equity movements in medicine 38:09 If someone could only listen to the last minute of this episode, what would you want them to take away? 44:14 How to contact Roizen and get his book 45:03 Thanks for listening 46:16 Michael F. Roizen, MD, is the emeritus chief wellness officer at the Cleveland Clinic, a professor at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, and author of four #1 New York Times best-selling books. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Roizen can be reached via email at info@greatagereboot.com, or on the website GreatAgeReboot.com. Find The Great Age Reboot: Cracking the Longevity Code for a Younger Tomorrow wherever you get your books! Disclosures: Jain reports no relevant financial disclosures. Healio could not confirm Roizen's financial disclosures at the time of publication.

Send us a Text Message."There's no other me out there. I can learn things from everybody, but there's not the one person I can model for exactly what means something to me, what I'm good at, and what interests me." -Dr. Mary Rensel, MDOften we find ourselves trying to emulate others, and not tapping into our own creativity or our 'inner power'.  We are creative beings (humans). At times, we lack self belief, and it is run over by self doubt.  What if we could cultivate the belief in self?What if we could build an answer or solution to a larger problem?Small dents, from multiple individuals, can make a crater!I had the pleasure of speaking with Dr. Mary Rensel, MD, physician and creator of Brain Fresh LLC,  a neuroscience based professional development  support system.  She spoke about her innovation and inspiration behind Brain Fresh, as well as her peaks and valleys through her medical career.Discussed in this episode:Peaks and valleys in life.Different things worked at different times in career and home life.Prioritize.  Your own needs are important.Doing things of interest and that you love.Innovation/creating can be inspirational.  Sometimes things get stagnant.We are not always in the growth zone.There are some things that are non-negotiableEnsuring family, spiritual, health, work were balanced.Burnout has been around since 1970s.  going up and up.Earn CME:This experience is powered by CMEfy – an AI-powered platform that directs learners along a pathway to capture reflections at point of inspiration, point of care. Clinicians may earn CME/CE credit via ReflectCE, the accredited activity portal. https://earnc.me/N09rlZConnect with Dr. Mary RenselMary Rensel, MD is an Assistant Professor of Medicine at the Cleveland Clinic Lerner College of Medicine and Director of Pediatric Multiple Sclerosis and Wellness at the Mellen Center of the Cleveland Clinic. She has graduated from the Medical College of Ohio and completed her Neurology and Neuro-immunology fellowship training at the Cleveland Clinic. She is boarded in Neurology and Integrative Medicine and is a fellow of the American Academy of Neurology. Dr. Rensel's work has focused on Adult and Pediatric Multiple Sclerosis, Brain health and Integrative Medicine. Her work in academic medicine often intersects with wellness, advocacy, innovation, coaching and strategic initiatives. She is a “Best Doctor” of Cleveland since 2010 per the Cleveland Magazine.  She is the owner of Brain Fresh, a neuroscience based professional development  support system. Though I am a physician, this is not medical advice. This is only a tool that physicians can use to get ideas on how to deal with burnout and/or know they are not alone. If you are in need of medical assistance talk to your physician.Learn more about female physicians' journey through burnout to thriving!https://www.theworthyphysician.com/booksLet's connect for speaking opportunities!https://www.theworthyphysician.com/dr-shahhaque-md-as-a-speakerCheck out the free resources from The Worthy Physician:https://www.theworthyphysician.com/freebie-downloadsBattle of the Boxes21 Day Self Focus Journal

Dr Mary Rensel, MD, is the founder of Brain Fresh, a brain-based time management system for busy professional women for enhanced joy and peace.She is co-founder of Brain Ops Group, a group focused on optimizing brain performance to achieve better business outcomes. She is an Assistant Professor of Neurology at the Cleveland Clinic Lerner College of Medicine and Director of Pediatric Multiple Sclerosis and Wellness of the Mellen Center of the Cleveland Clinic.She graduated from the Medical College of Ohio and completed her Neuroimmunology fellowship training at the Cleveland Clinic.  She is board-certified in both Neurology and Integrative Medicine and is a fellow of the American Academy of Neurology.Dr. Rensel's work has focused on Adult and Pediatric Multiple Sclerosis, Brain Health and Integrative Medicine.  Her work in academic medicine often intersects with wellness, advocacy, innovation, entrepreneurship and strategic initiatives. She has been the "Best Doctor" in Cleveland since 2010 as per the Cleveland Magazine. She is the Past President of the Women's Professional Staff Association of the Cleveland Clinic. She is active as an Advanced Peer Coach, mentor, scientific reviewer, clinical researcher, activity director, book editor, entrepreneur and national speaker. She has appeared on numerous media outlets including Good Morning America.In this episode, Dr Rensel and I chat about:Her leadership roles Her leadership style Her leadership journey The leaders that helped her rise The challenges she faced on her journey How she navigated those challenges How she thinks you can become a strong and kind leader Her 'take home' leadership messages for the listeners, and What she is currently excited to be working on.Dr Rensel can be contacted via Dr.MaryRensel@gmail.com and her social media links can be found on Linktree - https://linktr.ee/Dr.MaryRensel Please reach out to Dr Harrison for individual coaching and/or organisational training via dr.adam@coachingmentoringdoctors.com.His web address and social media profile links / handles include:www.dradamharrison.comhttps://www.linkedin.com/in/dradamharrison/www.youtube.com/c/DrAdamPhysicianCoachhttps://www.facebook.com/coachingmentoringdoctors/https://www.instagram.com/dradamharrison/https://www.tiktok.com/@physiciancoach

Dr. Sumita Khatri is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, Vice Chair of Cleveland Clinic's Respiratory Institute, Director of the Asthma Center and a practicing Adult Pulmonary and ICU physician. She serves on the national board of the American Lung Association and is founder of FLEX, a leadership development program for women faculty of the Case Western Reserve University School of Medicine. She is truly a visionary and a transformational leader and discusses the importance of building credibility and trust with colleagues and patients, and having the confidence to live your purpose with authenticity, humor and empathy.

With the advent and rapid evolution of contemporary percutaneous coronary intervention (PCI), the early invasive management of acute myocardial infarction (AMI) has become a mainstay in therapy with significant impact on patient outcomes. However, despite modern advances in technology and system-based practices, AMI presenting with cardiogenic shock (CS) continues to portend a high risk of morbidity and mortality. Few randomized controlled clinical trials are available to guide decision-making in this uniquely challenging patient population. Understanding the pathophysiologic mechanism by which injury occurs and propagates the shock cycle can be instrumental in selecting an appropriate strategy for revascularization and left ventricular unloading. In this episode we are joined by Dr. Venu Menon, The Mehdi Razavi Endowed Chair and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine,  section head of clinical cardiology, fellowship program director, and director of the Cardiac intensive care unit at the Cleveland Clinic. Dr. Menon shares his wealth of knowledge and experience to help us review the contemporary data available for AMI CS management in a case-based discussion. We are also joined by Dr. Priya Kothapalli, star chief fellow and future interventionalist from University of Texas at Austin, series co-chair Dr. Yoav Karpenshif, and CardioNerds Co-founders Amit Goyal and Daniel Ambinder. Audio editing by CardioNerds Academy Intern, Dr. Christian Faaborg-Andersen. The CardioNerds Cardiac Critical Care Series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Mark Belkin, Dr. Eunice Dugan, Dr. Karan Desai, and Dr. Yoav Karpenshif. Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Cardiac Critical Care PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Approach to Acute Myocardial Infarction Cardiogenic Shock with Dr. Venu Menon The H&P does matter! Age, location of infarction, heart rate, systolic blood pressure, and heart failure symptoms all carry weight in determining prognosis and risk of mortality.Define functional status, comorbid conditions, and life expectancy to help guide clinical decision-making. Do a quick bedside echocardiogram if possible to elucidate the predominant mechanism driving CS and rule out mechanical complications.Act with urgency! Get to the catheterization lab to characterize coronary anatomy and revascularize the culprit vessel as soon as possible.Minimize/avoid the use of vasopressors; if needed, wean as quickly as possible to avoid worsening myocardial ischemia. Consider mechanical circulatory support early!Despite dramatic advances in AMI management, data is limited in AMI CS management. Ask the important questions, get involved in the scientific inquiry as a trainee! Show notes - Approach to Acute Myocardial Infarction Cardiogenic Shock with Dr. Venu Menon 1. Why is it important to recognize AMI complicated by CS? AMI CS occurs in 7-10% of patients presenting with AMI and has a higher prevalence among elderly patients.The SHOCK trial (1999) showed significant survival benefit at 6 months with early revascularization with balloon angioplasty compared to medical therapy alone in AMI CS.Registry data suggests that early revascularization is beneficial in AMI CS even in elderly patients. Decision-making should be guided using a holistic view of the patient's overall biology.Despite advances in revascularization techniques and availability of mechanical support, AMI CS portends a 40-45% risk of 30-day mortality in the modern era.Significant variation in management strategy exists between centers and data to guide decision-making is limi...

GuestDr. Seth BauerClinical Pharmacist, Department of Pharmacy, Cleveland Clinic, Clinical Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine;HostMarilyn N. Bulloch, PharmD, BCPS, FCCMAssociate Clinical Professor and Director of Strategic OperationsHarrison College of Pharmacy | Auburn University

Now retired, Kandice Kottke Marchant, MD, PhD, served as Chair of the Institute of Pathology and Laboratory Medicine and is Professor of Pathology at Cleveland Clinic Lerner College of Medicine. She talks candidly about her experience with grief, the isolation of being a leader and the unprecedented way she stepped down from leadership…which has allowed her to pursue her passion for cheese making and start her next chapter as a small business owner with a flourishing cheese shop on Cleveland's east side.

Psoriasis can be a very isolating condition that causes a lot of shame. My guest today will discuss how and why psoriasis can affect mental health and even lead to depression. My guest today, Dr. Fabrizio Galimberti, completed his medical training at Cleveland Clinic Lerner College of Medicine-Case Western Reserve University, received his doctorate degree from Dartmouth College and his residency at the Jackson Memorial Hospital-University of Miami Miller School of Medicine where he also served as chief resident. Dr. Galimberti's research interests include oncodermatology, autoimmune connective tissue diseases, and impact on quality of life of dermatologic conditions. He has published numerous articles in prestigious journals as well as presented his work at international conferences. Join us as we discuss the connection between psoriasis and depression. Has psoriasis affected your mental health? Let me know in the comments! In this episode: How does psoriasis affect quality of life? Does psoriasis affect how people see themselves? Ways psoriatic arthritis affects quality of life The connection between psoriasis and depression Benefits of being active and getting outside if you have psoriasis Quotes “Genital psoriasis is something that it even leads to lower quality of life, and even more sensation of stigma. These patients do not want to have sexual intercourse with their partners, or they stop seeking out for partners because they're embarrassed or because they feel that they're going to be judged because of that rash.” [5:26] “Musical therapy has been shown in multiple studies to help improve the skin clearance in psoriasis.” [20:13] Links Dr. Galimberti can be found at this email address: fxg331@med.miami.edu Book Appointment (umiamihealth.org)

THERE IS AN AUDIO issue but we decided to put it out because the information is so good! Excited to talk about multiple sclerosis (MS) with Dr. Rensel. MS is a disease that impacts the brain and spinal cord which make up the central nervous system and controls everything we do. Some estimates indicated that nearly 1M adults in the US have MS so this is one reason, we wanted to learn more from an expert. Mary Rensel, MD is an owner of Brain Fresh, a Coach Tool Kit based on brain based research. She is co-owner of Brain Ops Group, a group focused on optimizing brain performance to achieve better business outcomes. She is an Assistant Professor of Neurology at the Cleveland Clinic Lerner College of Medicine and Director of Pediatric Multiple Sclerosis and Wellness of the Mellen Center of the Cleveland Clinic. She has graduated from the Medical College of Ohio and completed her Neuroimmunology fellowship training at the Cleveland Clinic. She is boarded in Neurology and Integrative Medicine and is a fellow of the American Academy of Neurology. Dr. Rensel's work has focused on Adult and Pediatric Multiple Sclerosis, Brain Health and Integrative Medicine. Her work in academic medicine often intersects with wellness, advocacy, innovation, entrepreneurship and strategic initiatives. She is the "Best Doctor" of Cleveland since 2010 per the Cleveland Magazine. She is the Past President of the Women's Professional Staff Association of the Cleveland Clinic. She is active as an Advanced Peer Coach, mentor, scientific reviewer, clinical researcher, activity director, book editor, entrepreneur and national speaker. She has appeared on numerous media outlets including Good Morning America. Connect with Dr. Rensel Websites: https://www.brainopsgroup.com https://www.brainfresh.org Facebook: https://www.facebook.com/mary.rensel.9 Twitter @MRenselMD www.linkedin.com/in/mary-rensel-94844b1a --- Send in a voice message: https://anchor.fm/urcaringdocs/message

In this episode, Joel M. Gelfand, MD, MSCE, is joined by Leonard H. Calabrese, DO, and Amesh Adalja, MD, FIDSA, as they discuss quarantine and isolation guidelines, emerging therapies to treat COVID-19, and the anticipated future of the COVID-19 pandemic. Welcome from Joel Gelfand, MD, MSCE :10 About Calabrese and Adalja :11 At day five, what's your recommendation for clinicians how to counsel people about testing to get out of isolation? Do you recommend people go ahead and get tested to end isolation or to just end isolation if not having much symptoms or improving? :51 How should we counsel our immunocompromised patients? Should they really isolate for 20 days? 5:21 Can people continue to test positive and antigen test beyond the infectious period? 10:13 In the clinical setting, you know, should physicians be wearing N95 masks, and if so, what's that databased on? 15:22 If a person has a positive antigen test but a negative PCR on the same day, how do you interpret that information for a patient? 22:12 Now we finally have emergence of effective therapies for people with COVID-19. How do you think about these different therapies? Do you have an algorithm that you'd recommend to clinicians in the field about which one to reach for first? 24:05 When someone has a COVID infection how soon thereafter can you give them a COVID immunization? 27:47 With Omicron working its way through the US and obviously through the world, where do you see the next three to six months going? 28:34 Thank you everyone 31:29 Amesh Adalja, MD, FIDSA,is senior scholar at Johns Hopkins and a practicing infectious disease and critical care physician in Pittsburgh. Leonard H. Calabrese, DO, is chief medical editor of Healio Rheumatology, professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer Chair of Clinical Immunology at the Cleveland Clinic. Joel M. Gelfand, MD, MSCE, is chief medical editor of Healio Psoriatic Disease and professor of dermatology and epidemiology at the Perelman School of Medicine at the University of Pennsylvania. He is also vice chair of clinical research, medical director at the Dermatology Clinical Studies Unit, and director of the Psoriasis and Phototherapy Treatment Center at Penn Medicine. We'd love to hear from you! Send your comments/questions to Dr. Gelfand, Calabrese and Adalja at covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews, @GoHealio, @DrJoelGelfand, @LCalabreseDO and @AmeshAA. Disclosures: Adalja reports no relevant financial disclosures. Calabrese reports consulting for AstraZeneca, GSK and Regeneron. Gelfand reports serving as a consultant for Abcentra, Abbvie, BMS, Boehringer Ingelheim, GSK, Lilly (DMC), Janssen Biologics, Novartis Corp, UCB (DSMB), Neuroderm (DSMB), Trevi, and Mindera Dx., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Boehringer Ingelheim, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly pharmaceutical sponsors. Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. Gelfand is a deputy editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology, is chief medical editor for Healio Psoriatic Disease (receiving honoraria) and is a member of the Board of Directors for the International Psoriasis Council, receiving no honoraria.